<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5258">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153633</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-G-H 0901</org_study_id>
    <nct_id>NCT01153633</nct_id>
  </id_info>
  <brief_title>Trial on the Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel</brief_title>
  <official_title>Pilot, Randomised, Double-blind, Controlled Clinical Trial on the Combined Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel in the Reduction in Size and Change in Bioburden of Hard-to-heal Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Ltd. Centre of Excellence Infection Control</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Ltd. Centre of Excellence Infection Control</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of Prontosan® Wound
      Irrigation Solution and Prontosan® Wound Gel in the treatment of hard-to heal venous leg
      ulcers compared to control saline irrigation solution and inactive gel by showing a
      reduction in size over a 12 week period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SUMMARY

      Sponsor: B. BRAUN Medical AG

      Trade name: Prontosan® Wound Irrigation Solution Prontosan® Wound Gel

      Active substance: Polihexanide (0.1%) Betaine (0.1%)

      Study Duration (per patient):

      13 weeks, including the 1 week run in period

      Primary Objective:

      To evaluate the efficacy of the combination of Prontosan® Wound Irrigation Solution and
      Prontosan® Wound Gel in the reduction of wound size of hard-to-heal venous leg ulcers
      compared to control saline irrigation solution and inactive gel.

      Secondary Objectives:

      To assess the change in bio-burden (assessment of organisms present) and to determine local
      tolerance as well as reduction in pain and to monitor exudate control.

      Methodology:

      A pilot randomised, double-blind, controlled clinical trial at a single centre

      Planned number of patients:

      A sample size of N= 15 evaluable patients was estimated for each treatment group (group &quot;A&quot;
      and &quot;B&quot;). Adding a dropout rate of approx. 25% results in a total number of patients for
      both treatment groups of N=38.

      Study Visits:

      Visit 0 (-1 week) - Screening Visit 1 ( Week 0) - Treatment and assessment visit Visit 2
      (Week 1, day 7 +/- 1 day) - Treatment and assessment visit Visit 3 (Week 2, day14 +/- 1 day)
      - Treatment and assessment visit Visit 4 (Week 4, day 28 +/- 2 days) - Treatment and
      assessment visit Visit 5 (Week 8, day 56 +/- 2 days) - Treatment and assessment visit Visit
      6 (Week 12, day 84 +/- 2 days) - End of study following 12 weeks of treatment or at healing
      whichever is soonest

      The number of additional visits will be recorded in the Case Report Forms.

      Treatment efficacy assessment:

      Clinical signs and symptoms will be compared between the two randomised groups with
      microbiological analysis and, computer planimetry assessments of ulcer size, using Visitrak™
      (Smith &amp; Nephew), and digital photography at entry to the study, at each planned study visit
      and at healing or 12 weeks, whichever is soonest.

      Tolerance assessment:

      The tolerability of study treatment will be evaluation based on the intensity and the course
      of adverse events (undesired concomitant effects, both subjectively perceived symptoms and
      objectively detected signs of disease). Tolerance assessments will take place from visit 2
      onwards

      Assessment methods:

        1. Assessment of clinical signs and symptoms, in particular related to development of
           infection:

             -  reduction of slough and necrotic tissue

             -  control of exudate

             -  presence of granulation tissue

             -  reduction of inflammatory signs (surrounding skin)

             -  pain

        2. Ulcer computerised planimetry using Visitrak™

        3. Microbiological analysis for bioburden (the bioburden within an ulcer relates to a
           microbiological qualitative and quantitative assessment of organisms present) assessed
           by wound swab or biopsy

        4. Serial photography with blinded assessment of progress using linear analogue scale
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change of Wound Size From Baseline to Last Visit</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing of Target Ulcer atV6/EOS</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of ulcers healed at V6/EOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change of Target Ulcer From Baseline to Last Visit</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Different Microganisms at V6/EoS</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute change (mm VAS) from baseline to V6/EoS. Pain intensity assessed by patient. At each study visit the patients assessed their pain intensity using a 100 mm Visual Analogue Scale (VAS). Thereby 0 mm represented 'no pain' and 100 mm 'worst possible pain'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Condition of Wound Bed</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sum of granulation and epithelium (% of wound bed), absolute change from baseline to V6/EoS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Prontosan Wound Solution and Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline and Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prontosan Wound Irrigation Solution and Prontosan Wound Gel</intervention_name>
    <description>The treatment procedures (after a 1 week run-in) include:
Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation
Secondary dressing to be a semi occlusive dressing
Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.</description>
    <arm_group_label>Prontosan Wound Solution and Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Normal Saline and Placebo Gel</intervention_name>
    <description>The treatment procedures (after a 1 week run-in) include:
Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation
Secondary dressing to be a semi occlusive dressing
Secure the dressing to the wound with tubifast and short stretch compression system
Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.</description>
    <arm_group_label>Normal Saline and Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged &gt; 18 who are able to give informed consent

          -  Patients with a chronic venous leg ulcer at any location below the knee joint (CVI
             grade C6 according to CEAP classification = trophic lesions and open ulcer)

          -  Venous leg ulcer present for ≥4 weeks

          -  Surface area of the target ulcer ≥2cm2 and &lt;100cm2 with the largest length not being
             &gt;10cm

          -  ABPI ≥ 0.7

        Exclusion Criteria:

          -  Age below 18 years

          -  Females of child bearing potential who are not willing to use a method of highly
             effective contraception during the entire study

          -  Pregnant or breast feeding women

          -  Signs and symptoms of clinical infection, or current use of antiseptics or
             antibiotics

          -  Involvement in other trials within the past 1 month

          -  Sensitivity to any of the components of Prontosan® or dressing material

          -  Intolerance to compression therapy

          -  Active osteomyelitis in the ulceration area

          -  Active rheumatoid or collagen disease of blood vessels treated with corticosteroids

          -  Chronic diseases that could impact the course of the study (malicious cancer, TB,
             AIDS, mental illnesses)

          -  Plasma protein below 4 g/dl

          -  Anaemia: haemoglobin below 10 g/dl

          -  Poorly controlled Diabetes (HBA1C &gt; 12%)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Harding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiff University, Department of Wound Healing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiff University, Department of Wound Healing</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>June 28, 2010</firstreceived_date>
  <firstreceived_results_date>May 29, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prontosan Wound Solution and Gel</title>
          <description>Polihexanide (0.1%), Betaine (0,1%), Purifed water</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline and Placebo Gel</title>
          <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapeutic failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prontosan Wound Solution and Gel</title>
          <description>Polihexanide (0.1%), Betaine (0,1%), Purifed water</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline and Placebo Gel</title>
          <description>Sodium Choride 0.9% Solution, Neutral Gel without Polihexanide, without Betaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="71.1" spread="9.6"/>
                <measurement group_id="B2" value="73.1" spread="10.7"/>
                <measurement group_id="B3" value="71.6" spread="10.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration of leg ulceration</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36" lower_limit="5" upper_limit="360"/>
                <measurement group_id="B2" value="84" lower_limit="3" upper_limit="84"/>
                <measurement group_id="B3" value="54" lower_limit="3" upper_limit="384"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change of Wound Size From Baseline to Last Visit</title>
        <time_frame>12 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Prontosan Wound Irrigation Solution and Gel</title>
            <description>Polihexanide 0.1%, Betaine 01.%, purified water, exipients</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline and Inactive Gel</title>
            <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change of Wound Size From Baseline to Last Visit</title>
            <units>percentage change in wound size (cm2)</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-64.98" spread="12.32"/>
                  <measurement group_id="O2" value="-42.78" spread="13.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2317</p_value>
            <p_value_desc>F-test (2-sided), ANCOVA with baseline target ulcer size as covariate</p_value_desc>
            <method>F-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Different Microganisms at V6/EoS</title>
        <time_frame>12 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Prontosan Wound Solution and Gel</title>
            <description>Polihexanide 0.1%, Betaine 0.1%, purified water, exipients</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline and Placebo Gel</title>
            <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Different Microganisms at V6/EoS</title>
            <units>Number of microgasism species</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.8" spread="0.9"/>
                  <measurement group_id="O2" value="1.0" spread="0.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Absolute change (mm VAS) from baseline to V6/EoS. Pain intensity assessed by patient. At each study visit the patients assessed their pain intensity using a 100 mm Visual Analogue Scale (VAS). Thereby 0 mm represented ‘no pain’ and 100 mm ‘worst possible pain’.</description>
        <time_frame>12 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Prontosan Wound Solution and Gel</title>
            <description>Polihexanide 0.1%, Betaine 0.1%, purified water, exipients</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline and Placebo Gel</title>
            <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain</title>
            <description>Absolute change (mm VAS) from baseline to V6/EoS. Pain intensity assessed by patient. At each study visit the patients assessed their pain intensity using a 100 mm Visual Analogue Scale (VAS). Thereby 0 mm represented ‘no pain’ and 100 mm ‘worst possible pain’.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.9" spread="20.4"/>
                  <measurement group_id="O2" value="-12.8" spread="26.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Condition of Wound Bed</title>
        <description>Sum of granulation and epithelium (% of wound bed), absolute change from baseline to V6/EoS</description>
        <time_frame>12 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Prontosan Wound Solution and Gel</title>
            <description>Polihexanide 0.1%, Betaine 0.1%, purified water, exipients</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline and Placebo Gel</title>
            <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Condition of Wound Bed</title>
            <description>Sum of granulation and epithelium (% of wound bed), absolute change from baseline to V6/EoS</description>
            <units>percentage of of wound bed</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.1" spread="38.9"/>
                  <measurement group_id="O2" value="-1.5" spread="52.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Healing of Target Ulcer atV6/EOS</title>
        <description>Number of ulcers healed at V6/EOS</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Prontosan Wound Solution and Gel</title>
            <description>Polihexanide 0.1%, Betaine 0.1%, purified water, exipients</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline and Placebo Gel</title>
            <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Healing of Target Ulcer atV6/EOS</title>
            <description>Number of ulcers healed at V6/EOS</description>
            <units>ulcers</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4905</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change of Target Ulcer From Baseline to Last Visit</title>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Prontosan Wound Solution and Gel</title>
            <description>Polihexanide 0.1%, Betaine 0.1%, purified water, exipients</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline and Placebo Gel</title>
            <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Absolute Change of Target Ulcer From Baseline to Last Visit</title>
            <units>square centimeters</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-3.00" spread="1.45"/>
                  <measurement group_id="O2" value="-3.01" spread="1.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9945</p_value>
            <p_value_desc>F-test (2-sided), ANCOVA with baseline target ulcer size as covariate</p_value_desc>
            <method>F-test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prontosan Wound Solution and Gel</title>
          <description>Polihexanide 0.1%, Betaine 0.1%, purified water, exipients</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline and Placebo Gel</title>
          <description>Sodium Chloride 0.9% Solution Inactive Hydrogel, Hydroxyethylcellulose, Glycerol, purified water, exipients</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Celulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Excessive granulation tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin maceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Venous ulcer pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin chapped</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Most likely the non-statistical significant results are due to the small sample size. No sample size calculation and statistical analysis was planned a priori because it was a pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Scientific Affairs Manager</name_or_title>
      <organization>B. Braun Medical AG</organization>
      <phone>+41 58 258 55 47</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
